In a complex transaction announced on January 16, Katten represented generic medicines manufacturer Sawai Pharmaceutical in connection with the sale of Upsher-Smith Laboratories, a manufacturer of generic and specialty branded drugs based in Minnesota. Sumitomo Corporation of Americas, a co-investor in Sawai America LLC, will transfer its interests to Bora as part of the transaction.

The deal, valued at $210 million, is subject to approval from regulators.

The Katten team representing Sawai, Sumitomo, and Upsher-Smith was led by Intellectual Property Partner Brian Sodikoff, co-chair of Patent Litigation, along with Antitrust and Competition Partner James Calder, Litigation Partner Jonathan Rotenberg and Associate Zachary Beal.

"Notice of Transfer (Sale of Shares/Equity Interests) of Sawai's U.S. Subsidiary / Sub-subsidiary," Upsher-Smith, January 16, 2024

"Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion," Bora Pharmaceuticals, January 16, 2024